Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVONASDAQ:ATHXNASDAQ:ATXINASDAQ:OCEA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$3.46+6.5%$7.88$2.81▼$485.37$2.46M5.75599,182 shs1.19 million shsATHXAthersys$0.00$0.01▼$1.99$833K-0.91.77 million shs23,261 shsATXIAvenue Therapeutics$0.24+0.2%$0.24$0.17▼$3.93$766K-0.09130,945 shs14,118 shsOCEAOcean Biomedical$0.01+6.8%$0.00$0.01▼$1.46$272K1.3117.12 million shs951,073 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-22.06%-11.20%-40.99%-90.92%-99.98%ATHXAthersys0.00%0.00%0.00%0.00%-69.70%ATXIAvenue Therapeutics-19.65%+11.62%+14.99%-33.86%-92.85%OCEAOcean Biomedical0.00%-7.59%-5.19%-87.52%-99.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics3.2621 of 5 stars3.55.00.00.02.90.01.3ATHXAthersysN/AN/AN/AN/AN/AN/AN/AN/AATXIAvenue Therapeutics1.7508 of 5 stars0.03.00.04.61.10.01.9OCEAOcean Biomedical0.5231 of 5 stars0.05.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.006,330,535.84% UpsideATHXAthersys 0.00N/AN/AN/AATXIAvenue Therapeutics 0.00N/AN/AN/AOCEAOcean Biomedical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.85N/AN/A$65.21 per share0.05ATHXAthersys$146K0.00N/AN/A($1.33) per share0.00ATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AOCEAOcean BiomedicalN/AN/AN/AN/A($2.62) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)ATHXAthersys-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/AATXIAvenue Therapeutics-$10.38M$18.350.01∞N/AN/A-471.57%-296.50%8/7/2025 (Estimated)OCEAOcean Biomedical-$114.47M-$0.94N/A∞N/AN/AN/A-931.55%N/ALatest OCEA, APVO, ATHX, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A4/8/2025Q4 2024OCEAOcean BiomedicalN/A$0.02N/A$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AATHXAthersysN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/AOCEAOcean BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A0.670.67ATHXAthersysN/A0.060.06ATXIAvenue TherapeuticsN/A2.702.70OCEAOcean BiomedicalN/A0.030.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%ATHXAthersys19.35%ATXIAvenue Therapeutics17.34%OCEAOcean Biomedical24.55%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.12%ATHXAthersys0.03%ATXIAvenue Therapeutics1.80%OCEAOcean Biomedical73.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics50760,000755,000Not OptionableATHXAthersys2461.72 million61.70 millionNo DataATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableOCEAOcean BiomedicalN/A34.87 million9.24 millionOptionableOCEA, APVO, ATHX, and ATXI HeadlinesRecent News About These CompaniesNew study explains why your skin feels tight at the beach: It's the salt waterJune 24 at 10:15 PM | msn.comStudy unlocks anti-cancer and anti-inflammatory potential of soft coralsJune 16, 2025 | phys.orgBiomedical Textiles Market to Surpass USD 28 Billion by 2032, Expanding at a CAGR of 6.2% from 2024June 16, 2025 | taiwannews.com.twOcean Biomedical faces license terminations over breachesJune 15, 2025 | kalkinemedia.comStudy Unlocks Soft Corals’ Biomedical PotentialJune 13, 2025 | scripps.ucsd.eduOcean Biomedical Faces License Termination NoticeJune 13, 2025 | tipranks.comUC San Diego scientists develop gel to attract baby coral, encourage reef growthMay 15, 2025 | msn.comLatest Ocean Biomedical Stock News | NASDAQ:OCEA | BenzingaApril 24, 2025 | benzinga.comOcean Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder ValueApril 22, 2025 | manilatimes.netOcean Biomedical Inc.April 1, 2025 | barrons.comOcean Biomedical secures key patent in China for cancer therapyMarch 30, 2025 | uk.investing.comOcean Biomedical granted notice of grant on patent right by CNIPAMarch 30, 2025 | markets.businessinsider.comOcean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in ChinaMarch 28, 2025 | markets.businessinsider.comFour board members to exit troubled RI biotechMarch 27, 2025 | bizjournals.comOcean Biomedical announces board reshuffle amid resignationsMarch 12, 2025 | investing.comOcean Biomedical reports unregistered equity salesFebruary 13, 2025 | msn.comOcean Biomedical advances in cancer immunotherapyFebruary 11, 2025 | msn.comOcean Biomedical announces findings in EGFR-mutant lung cancerFebruary 11, 2025 | markets.businessinsider.comOcean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage DevelopmentFebruary 10, 2025 | globenewswire.comWhy Is Ocean Biomedical Inc (OCEA) Stock Lagging Behind -67.33% from Its 50-Day SMA?February 3, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeA Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesBy Gabriel Osorio-Mazilli | June 6, 2025View A Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesHigher Gulf Oil Output Puts These Energy Names in PlayBy Gabriel Osorio-Mazilli | June 13, 2025View Higher Gulf Oil Output Puts These Energy Names in PlayOCEA, APVO, ATHX, and ATXI Company DescriptionsAptevo Therapeutics NASDAQ:APVO$3.46 +0.21 (+6.46%) Closing price 04:00 PM EasternExtended Trading$3.47 +0.01 (+0.32%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Athersys NASDAQ:ATHXAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Avenue Therapeutics NASDAQ:ATXI$0.24 +0.00 (+0.17%) As of 03:11 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Ocean Biomedical NASDAQ:OCEAAesther Healthcare Acquisition Corp. entered into definitive merger agreement with Ocean Biomedical, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
